These findings indicate that hepatic-specific overexpression of PGC-1α exerts a beneficial role in the regulation of steatohepatitis and that pharmacological activation of the SIRT2-PGC-1α-NAD+ axis may help to treat NASH. The gene discussed is PPARGC1A; the disease is metabolic dysfunction-associated steatohepatitis.